FPP003 / FunPep, Sumitomo Pharma - LARVOL DELTA

Safety and immunogenicity of an adjuvant-free peptide vaccine targeting IL-17A: Phase 1 randomized controlled trial. (PubMed, iScience) - "Furthermore, circulating follicular helper T cells was significantly increased in the FPP003 high-dose group. The adjuvant-free FPP003 peptide vaccine could be well-tolerated and beneficial approach in human."

Journal • P1 data • IFNG • IL17A • IL4

FunPep announces the granting of a substance patent for the antibody-inducing peptide "FPP003" (Europe, divisional application) [Google translation] (Yahoo Finance) - "This divisional application was filed based on an existing substance patent with the aim of strengthening the rights of 'FPP003'.'FPP003' is an antibody-inducing peptide therapeutic vaccine expected to be effective in treating intractable chronic diseases."

Patent • Ankylosing Spondylitis • Psoriasis • Psoriatic Arthritis

Announcement of the grant of a substance patent for the antibody-inducing peptide "FPP003" (Europe, divisional application) [Google translation] (Nikkei) - "The substance patent broadly protects the substance itself, regardless of the use (target disease) of FPP004X...[Patent number] 4194007 (original patent number 3434279) (Note) Our company has been granted an exclusive license from National University Corporation Osaka University....The establishment of this patent will not affect the financial results for the fiscal year ending December 2025, but will support the development project of FPP003."

Patent • Ankylosing Spondylitis • Immunology

FunPep Research Memo (6): Sumitomo Pharma holds option rights for FPP003 in North America [Google translation] (Kabutan - Minkabu The Infonoid) - "This is an open-label, uncontrolled trial, and the subjects are patients with axial spondyloarthritis...The reason for targeting patients in remission is that if the administration of 'FPP003' can maintain remission, the use of expensive antibody drugs can be avoided, which will reduce the burden on patients and medical finances....The trial period is scheduled to end around March 2025, and the results are expected to be known within 2025."

P2a data • Trial completion date • Ankylosing Spondylitis